Floatz logo

Tas-102

Inflammatory Breast Cancer

University of WashingtonunclassifiedPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Inflammatory Breast Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Hoffmann-La Roche
Phase 3BBB
Cyclophosphamide
Northwestern University
Phase 3BBB
Carboplatin
Northwestern University
Phase 3BBB
Docetaxel
Association Tunisienne de lutte Contre le Cancer
Phase 3BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Hoffmann-La Roche
Phase 3BBB

View all 35 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →